Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Epidemiology and Infection|July 1, 2010
Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in BelgiumH Theeten, V Hutse, N Hens, et al.Epidemics|May 17, 2015
The social contact hypothesis under the assumption of endemic equilibrium: Elucidating the transmission potential of VZV in EuropeE Santermans, N Goeyvaerts, A Melegaro, et al.International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|November 22, 2015
Community-acquired pneumonia (CAP) hospitalizations and deaths: is there a role for quality improvement through inter-hospital comparisons?W Aelvoet, N Terryn, A Blommaert, et al.Journal of Medical Virology|November 24, 1999
Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccinesK Van Herck, P Beutels, P Van Damme, et al.Vaccine|December 6, 2016
Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in AustraliaJ F Reyes, J G Wood, P Beutels, et al.The Journal of Infectious Diseases|September 15, 2021
Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United KingdomF Zeevat, J Luttjeboer, J H J Paulissen, et al.Journal De Pharmacie De Belgique|June 27, 2013
[Opinions and attitudes of Flemish pharmacists and general practitioners towards INN prescribing. A survery in Antwerp and East Flanders]J Fraeyman, J De Winter, H De Loof, et al.Medecine Et Maladies Infectieuses|May 26, 2005
[Varicella-zoster virus seroprevalence in nursery and day-care workers in Lyon (France)]F Reignier, L Romanò, N Thiry, et al.Epidemiology and Infection|May 8, 2019
The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis A virus seroprevalenceG S A Smit, S Abrams, P Dorny, et al.Vaccine|July 12, 2017
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older AustraliansS Dirmesropian, J G Wood, C R MacIntyre, et al.Pageof 5